Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas. (PubMed, Blood Adv) - Sep 25, 2026 - "CRS occurred in 31% (Grade 3+: 5%) and ICANS in 8% (Grade 3+: 2%) of patients, with no significant differences across glofitamab, mosunetuzumab, or epcoritamab. All patients with Grade 3+ CRS had very high serum C-Reactive Protein (sCRP, ≥15 mg/L) and elevated ferritin (>336 ng/mL) when available. These findings identify candidate laboratory thresholds and treatment related factors that warrant prospection validation for risk stratification and outpatient BsAb administration."
Journal • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CRP
|
|
Adam Kidwell; Adit Dharia; Alexandra Noveihed; Ari Pelcovits; Brian T Hess; Colin J Thomas; Deborah M Stephens; Geoffrey Shouse; James A Davis; Jane N Winter; Jonathan Moreira; Jonathon B Cohen; Leo I Gordon; Lindsey A Fitzgerald; Matthew J Cortese; Megan M Herr; Megan Melody; Narendranath Epperla; Natalie S Grover; Nicole Altomare; Nirav N Shah; Reem Karmali; Shuo Ma; Tamara K Moyo; Thomas A Ollila; Urmi Ghosh; Vaishalee P Kenkre; Victoria Anne Gill; Yun Kyoung Ryu Tiger
|